BioScrip Q3 Loss Wider than Expected; Strategic Plan in Focus

BioScrip Q3 Loss Wider than Expected; Strategic Plan in Focus Core and chronic blood therapies under its clinical programs increased $ 6.4 million sequentially with strong increase in patient census while Hepatitis C revenues witnessed a decline of $ 8.4 … Continue reading